Education
About Us
Working with TipRanks
Follow Us
DBV Technologies SA - American (DBVT)
NASDAQ:DBVT
DBVT Stock Chart & Stats
$14.04
$0.34(9.80%)
At close: 4:00 PM EST
$14.04
$0.34(9.80%)
Day’s Range― - ―
52-Week Range$2.20 - $18.00
Previous CloseN/A
Volume52.91K
Average Volume (3M)165.00K
Market Cap
$537.18M
Enterprise Value$179.04M
Total Cash (Recent Filing)$69.84M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.08
Next Earnings
Mar 05, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding35,965,584
10 Day Avg. Volume116,176
30 Day Avg. Volume165,002
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.17
Price to Sales (P/S)23.14
P/FCF Ratio-0.56
Enterprise Value/Market Cap0.33
Enterprise Value/Revenue350.36
Enterprise Value/Gross Profit-20.86
Enterprise Value/Ebitda-2.09
Forecast
1Y Price Target
$20.00Price Target Upside42.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-2.28
Revenue Forecast (FY)$4.88M
Bulls Say, Bears Say
Bulls Say
Market OpportunityThe market opportunity for Viaskin Peanut is sizable, with caregivers highly motivated to treat and current options being burdensome.
Regulatory MomentumA positive VITESSE readout could unlock both regulatory momentum and warrant-linked capital, extending runway into commercialization.
Safety StudyWith FDA alignment, COMFORT Toddlers is now a streamlined safety study rather than a full efficacy trial, lowering execution risk.
Bears Say
DBV Technologies SA - American News
DBVT FAQ
What was DBV Technologies SA - American’s price range in the past 12 months?
DBV Technologies SA - American lowest stock price was $2.20 and its highest was $18.00 in the past 12 months.
What is DBV Technologies SA - American’s market cap?
DBV Technologies SA - American’s market cap is $537.18M.
When is DBV Technologies SA - American’s upcoming earnings report date?
DBV Technologies SA - American’s upcoming earnings report date is Mar 05, 2026 which is in 117 days.
How were DBV Technologies SA - American’s earnings last quarter?
DBV Technologies SA - American released its earnings results on Oct 28, 2025. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.318 by $0.078.
Is DBV Technologies SA - American overvalued?
According to Wall Street analysts DBV Technologies SA - American’s price is currently Undervalued.
Does DBV Technologies SA - American pay dividends?
DBV Technologies SA - American does not currently pay dividends.
What is DBV Technologies SA - American’s EPS estimate?
DBV Technologies SA - American’s EPS estimate is -0.27.
How many shares outstanding does DBV Technologies SA - American have?
DBV Technologies SA - American has 35,965,584 shares outstanding.
What happened to DBV Technologies SA - American’s price movement after its last earnings report?
DBV Technologies SA - American reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.318. Following the earnings report the stock price went down -2.186%.
Which hedge fund is a major shareholder of DBV Technologies SA - American?
Currently, no hedge funds are holding shares in DBVT
DBV Technologies SA - American Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.00 (42.45% Upside)
$20.00 (42.45% Upside)
Blogger Sentiment
Bearish
DBVT Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 5.5%
Last 30 Days ▼ 5.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
264.67%
12-Months-Change
Fundamentals
Return on Equity
-234.58%
Trailing 12-Months
Asset Growth
18.74%
Trailing 12-Months
Company Description
DBV Technologies SA - American
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
DBVT Stock 12 Month Forecast
Average Price Target
$20.00
▲(42.45% Upside)
Technical Analysis
Larimar Therapeutics
―
Korro Bio
―
4D Molecular Therapeutics
―
PureTech Health
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
0.81% Insiders
0.02% Mutual Funds
10.88% Other Institutional Investors
88.30% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---